2024 - Go-To-Market Success: The Role of Capital Preservation in Life Science Research and Diagnostic Consumable Manufacturing
Date2024-04-25
Deadline2024-04-25
VenueONLINE-VIRTUAL, USA - United States
KeywordsLife Sciences; Pharma Manufacturing & Supply Chain; Medical Device
- Barcelona International Conference on Research in Life-Science & Healthcare, 05-06 August 2025
- Dubai International Conference on Research in Life-Science & Healthcare, 06-07 November 2025
- Scalable Functional Service Provider Solutions for Biopharma: Redefining Clinical Trial Success
- Paris International Conference on Research in Life-Science & Healthcare, 08-09 January 2025
- Berlin International Conference on Research in Life-Science & Healthcare, 21-22 June 2025
Topics/Call fo Papers
In this webinar, Patrick Tuohy will address a critical question encountered by most life science and diagnostic companies: Should the development and/or manufacturing of products be outsourced or in-sourced? The webinar delves into how a leading solutions provider for microfluidic devices and microarray assays can assist companies in saving capital and reducing time to market by outsourcing their development and manufacturing needs.
Business leaders in diagnostic and life science companies grapple with the challenging decision of how to produce their products. By focusing on core competencies, minimizing capital investments and embracing production flexibility, businesses can more efficiently navigate the journey from development to product launch by entering into collaborations.
In this webinar, the expert speakers will explore how life science and diagnostic companies can leverage pilot line capability. This capability consists of purpose-built manufacturing expertise within SCHOTT MINIFAB, enabling the transformation of clients’ products from initial assembled units (for feasibility testing) to the first commercial articles that contribute to improving patient health and well-being.
A common objection faced by companies is that insourcing is cheaper than outsourcing. It is crucial to understand the true costs, including those associated with capability development, facilities, equipment, administrative overhead and per capita expenses. In this webinar, the experts will thoroughly consider all relevant factors related to the development and manufacturing of products.
Register for this webinar to discover strategies for saving capital and reducing time to market in microfluidic device production and other life science consumables manufacturing.
Keywords: Microfluidic, IVD, Diagnostics, Laboratory Technology, Commercial Manufacturing, In Vitro Diagnostics, Microfluidics, Microfluidics-Based System, CDMO/CMO, Commercialization/HEOR/Market Access
Business leaders in diagnostic and life science companies grapple with the challenging decision of how to produce their products. By focusing on core competencies, minimizing capital investments and embracing production flexibility, businesses can more efficiently navigate the journey from development to product launch by entering into collaborations.
In this webinar, the expert speakers will explore how life science and diagnostic companies can leverage pilot line capability. This capability consists of purpose-built manufacturing expertise within SCHOTT MINIFAB, enabling the transformation of clients’ products from initial assembled units (for feasibility testing) to the first commercial articles that contribute to improving patient health and well-being.
A common objection faced by companies is that insourcing is cheaper than outsourcing. It is crucial to understand the true costs, including those associated with capability development, facilities, equipment, administrative overhead and per capita expenses. In this webinar, the experts will thoroughly consider all relevant factors related to the development and manufacturing of products.
Register for this webinar to discover strategies for saving capital and reducing time to market in microfluidic device production and other life science consumables manufacturing.
Keywords: Microfluidic, IVD, Diagnostics, Laboratory Technology, Commercial Manufacturing, In Vitro Diagnostics, Microfluidics, Microfluidics-Based System, CDMO/CMO, Commercialization/HEOR/Market Access
Other CFPs
- Clinical Data Strategy in Action for Complex Clinical Trials
- Providing Patients Equitable Access to Improve Inclusion in Clinical Trials
- Electromagnetic Compatibility and Radio Compliance for Medical Devices
- Helping to Decrease the Burden of Oncology Clinical Trials with Patient-Friendly Technologies
- Ensuring Your Biologics Assays Tell the Whole Story
Last modified: 2024-04-13 03:24:08